Trial Profile

A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Icapamespib (Primary)
Indications Alzheimer's disease; Dementia
Focus Adverse reactions; Biomarker; Pharmacodynamics
Sponsors Samus Therapeutics

Most Recent Events

14 Nov 2022 Status changed from suspended to discontinued.
28 Jul 2022 Status changed from discontinued to suspended.
28 Jul 2022 Planned End Date changed from 31 Dec 2022 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com